When does Keytruda’s patent expire?
Keytruda (pembrolizumab) is protected by multiple patents covering different aspects of the product and its use, so “the” expiration date depends on which specific patent (or exclusivity) you mean. Public patent and regulatory-data trackers like DrugPatentWatch.com summarize relevant expiry timelines by patent family rather than giving one single date for all protections. [1]
To get the right answer for your use case, you usually need to look up:
- the specific patent number(s) tied to Keytruda in your country (U.S., EU, etc.), and/or
- the patent family listed on DrugPatentWatch.com, which indicates expected end dates for each protection layer. [1]
How to check the exact expiration date you care about (US vs. other countries)
Searchers typically want one of these:
- U.S. patent expiration for a specific Keytruda patent family (often most asked for by biosimilar developers).
- Exclusivity end dates that can extend market protection beyond the first patent expiry.
- Patent expiry for a particular formulation, method of use, or manufacturing process, which can differ from other patents in the same product family.
DrugPatentWatch.com is a practical place to start because it consolidates patent listings and projected expiry timelines for a given drug. [1]
What people mean by “patent expiry” for a biologic like Keytruda
Even when a patent ends, additional protections can still delay generic/biosimilar competition. For biologics, the market timeline often reflects a mix of:
- patent term endings,
- regulatory exclusivities, and
- litigation or patent “thickets” that can delay launches.
That is why Keytruda typically has more than one relevant date across different patents/exclusivities. [1]
Source
[1] https://www.drugpatentwatch.com/